Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease (May 2024)

Moderate Aortic Valve Stenosis Is Associated With Increased Mortality Rate and Lifetime Loss: Systematic Review and Meta‐Analysis of Reconstructed Time‐to‐Event Data of 409 680 Patients

  • Xander Jacquemyn,
  • Jordan B. Strom,
  • Geoff Strange,
  • David Playford,
  • Simon Stewart,
  • Shelby Kutty,
  • Deepak L. Bhatt,
  • Sabine Bleiziffer,
  • Kendra J. Grubb,
  • Patricia A. Pellikka,
  • Marie‐Annick Clavel,
  • Philippe Pibarot,
  • Amgad Mentias,
  • Derek Serna‐Gallegos,
  • Michel Pompeu Sá,
  • Ibrahim Sultan

DOI
https://doi.org/10.1161/JAHA.123.033872
Journal volume & issue
Vol. 13, no. 9

Abstract

Read online

Background The mortality risk attributable to moderate aortic stenosis (AS) remains incompletely characterized and has historically been underestimated. We aim to evaluate the association between moderate AS and all‐cause death, comparing it with no/mild AS (in a general referral population and in patients with heart failure with reduced ejection fraction). Methods and Results A systematic review and pooled meta‐analysis of Kaplan–Meier‐derived reconstructed time‐to‐event data of studies published by June 2023 was conducted to evaluate survival outcomes among patients with moderate AS in comparison with individuals with no/mild AS. Ten studies were included, encompassing a total of 409 680 patients (11 527 with moderate AS and 398 153 with no/mild AS). In the overall population, the 15‐year overall survival rate was 23.3% (95% CI, 19.1%–28.3%) in patients with moderate AS and 58.9% (95% CI, 58.1%–59.7%) in patients with no/mild aortic stenosis (hazard ratio [HR], 2.55 [95% CI, 2.46–2.64]; P<0.001). In patients with heart failure with reduced ejection fraction, the 10‐year overall survival rate was 15.5% (95% CI, 10.0%–24.0%) in patients with moderate AS and 37.3% (95% CI, 36.2%–38.5%) in patients with no/mild AS (HR, 1.83 [95% CI, 1.69–2.0]; P<0.001). In both populations (overall and heart failure with reduced ejection fraction), these differences correspond to significant lifetime loss associated with moderate AS during follow‐up (4.4 years, P<0.001; and 1.9 years, P<0.001, respectively). A consistent pattern of elevated mortality rate associated with moderate AS in sensitivity analyses of matched studies was observed. Conclusions Moderate AS was associated with higher risk of death and lifetime loss compared with patients with no/mild AS.

Keywords